Compare Crispr Therapeutics AG (CRSP) vs Vipshop Holdings Ltd - ADR (VIPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Vipshop Holdings Ltd - ADR — how do they compare? Crispr Therapeutics AG trades at $50.61 (market cap $4.97B), while Vipshop Holdings Ltd - ADR trades at $13.43 (market cap $6.66B). The key difference: Vipshop Holdings Ltd - ADR is the larger of the two by market cap, and Vipshop Holdings Ltd - ADR pays a 4.47% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | VIPS | |
|---|---|---|
Market Cap | $4.97B | $6.66B |
Sector | Health | Consumer Cyclical |
52-Week High | $76.78 | $20.68 |
52-Week Low | $44.34 | $12.92 |
Enterprise Value | $3.32B | $3.25B |
Dividend Yield | — | 4.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
Vipshop Holdings (VIPS) trades at $13.92, down slightly by 0.14% on the day, with a bullish technical signal supported by strong ADX readings. The stock presents attractive valuation metrics with a P/E of 6.35 and P/S of 0.45, while maintaining solid profitability with an 18.43% ROE. Recent Q1 2026 earnings matched expectations, and the company is pursuing growth through outlet store spin-offs into a REIT structure.
The outlook remains positive given deep value multiples and analyst consensus leaning buy, though risks include revenue pressure from a later Chinese New Year and competitive e-commerce headwinds. Upside potential hinges on execution of the outlet strategy and return to sustained revenue growth in FY2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Vipshop Holdings Ltd - ADR
Vipshop Holdings Ltd is an online discount retailer for brands in China. The company offers branded products to consumers in China through flash sales on its vipshop.com, vip.com and lefeng.com websites. Flash sales represent an online retail format combining the advantages of e-commerce and discount sales through selling a finite quantity of discounted products or services online for a limited period of time. It deals in a wide range of products and services for consumers specializing in branded cosmetics, apparel, healthcare products, food and other consumer products. Its operating segment includes Vip.com and Shan Shan Outlets. The company generates maximum revenue from Vip.com segment.
Read more on VIPS →
